Defense Secretary Pete Hegseth says the U.S. military needs to rebuild what he calls a stronger “warrior ethos.”
His latest initiative is designed to do exactly that.
Under a new Pentagon policy, service members aged 30 and older will receive annual screenings for testosterone deficiency, while younger troops may request testing. Those diagnosed with clinically low testosterone can choose to undergo testosterone replacement therapy (TRT) under medical supervision.
Supporters describe the program as an effort to improve military readiness.
Critics immediately noticed something else.
The treatment being promoted is itself a form of hormone therapy the same broad category of medical care that has become central to the administration’s opposition to gender-affirming treatment for transgender Americans.
transphobic man wearing a face full of bronzer advertises new hormone replacement therapy options for cisgender male troops. everything is gender https://t.co/pck6QRDWmI
— matt bernstein (@mattxiv) July 15, 2026
What the New Policy Does
According to the Pentagon, the initiative includes:
- mandatory annual testosterone screening for troops aged 30 and older
- optional testing for younger service members
- voluntary testosterone replacement therapy for those diagnosed with testosterone deficiency
- medical oversight throughout treatment
Hegseth argues that maintaining healthy hormone levels can improve physical performance, recovery, and overall military readiness.
Rep. Balint on Hegseth's obsession with testosterone, his announcement of testosterone therapy for troops, and his attacks on women in combat:
— MeidasTouch (@MeidasTouch) July 16, 2026
"I think it is indicative of the fact that there are so many people in this administration that have some weird, intense, homoerotic,… pic.twitter.com/xS6hIya9Ue
Why Critics Call It Contradictory
The controversy isn’t about whether testosterone therapy exists.
It’s about who is allowed to receive hormone therapy and why.
The Trump administration has supported restrictions on gender-affirming care for transgender people in several contexts, including military service, while simultaneously expanding access to testosterone treatment for eligible male troops.
LGBTQ+ advocates argue that both treatments involve medically supervised hormone therapy prescribed for patients based on individual healthcare needs.
From their perspective, embracing one form of hormone treatment while condemning another reflects a political distinction rather than a medical one.
Supporters of the administration reject that comparison, arguing that testosterone replacement for clinically low hormone levels and gender-affirming care for transgender people serve different medical purposes and should not be treated as equivalent.
The High-T Department of War. pic.twitter.com/hlAUq3j2cD
— Secretary of War Pete Hegseth (@SecWar) July 15, 2026
Medical Experts Are Raising Separate Questions
Beyond the political debate, some physicians have questioned the science behind routine testosterone screening.
Endocrinologists note that testosterone levels naturally fluctuate throughout the day and decline gradually with age. Clinical guidelines generally recommend hormone therapy only after repeated testing confirms a true deficiency accompanied by symptoms.
Experts have also cautioned that testosterone therapy carries potential risks, including fertility reduction, cardiovascular concerns, and other side effects if used inappropriately.
The Culture War Quickly Followed
The policy almost immediately became another front in America’s ongoing debates over gender, healthcare, and the military.
Supporters praised Hegseth for prioritizing physical readiness among service members.
Critics argued that the initiative unintentionally highlighted what they see as an inconsistency in the administration’s broader healthcare policies.
Social media amplified the irony, with many users joking that the Pentagon had effectively endorsed one form of gender-related hormone treatment while opposing another.
Hormone Therapy Means Different Things in Different Contexts
One reason the debate has become so heated is that the phrase “hormone therapy” covers a wide range of medical treatments.
Testosterone replacement therapy is commonly prescribed for people diagnosed with hypogonadism or other conditions causing clinically low testosterone.
Gender-affirming hormone therapy is prescribed to help transgender patients align their physical characteristics with their gender identity.
While both involve hormones prescribed under medical supervision, they address different clinical conditions. Whether they should be treated similarly as a matter of public policy remains the central point of disagreement.
Another Flashpoint in a Broader Political Debate
The Pentagon’s testosterone initiative may have begun as a military health program.
Instead, it has become part of a much larger national conversation about medicine, gender, and government policy.
Supporters see an effort to improve force readiness through treatment for diagnosed hormone deficiencies.
Critics see a contradiction: support for hormone therapy in one setting alongside opposition to other forms of medically supervised hormone care.
The policy is still new, and its practical effects on recruitment, readiness, and military health remain to be seen.
What is already clear is that a proposal aimed at increasing testosterone levels has also reignited one of the country’s most contentious healthcare debates.